id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
8908396_3 | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[162]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"insulin\"]], \"start\": [[154]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"insulin\"]], \"start\": [[154]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"diabetic\"]], \"start\": [[189]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"lipoatrophies\"]], \"start\": [[170]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10891991_1 | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[160]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"women of reproductive age\"]], \"start\": [[72]], \"entity_id\": [\"T3\"], \"Gender\": {\"text\": [[\"women\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Age\": {\"text\": [[\"reproductive age\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"valproate for epilepsy\"]], \"start\": [[117]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"epilepsy\"]], \"start\": [[131]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"menstrual cycle disturbances\"]], \"start\": [[168]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
2332596_1 | Phenobarbital hepatotoxicity in an 8-month-old infant. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"an 8-month-old infant\"]], \"start\": [[32]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"8-month-old infant\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"Phenobarbital\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Phenobarbital\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hepatotoxicity\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
12552054_1 | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[100]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"intrathecal methotrexate and cytarabine\"]], \"start\": [[110]], \"entity_id\": [\"T9\"], \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[110]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"methotrexate\"], [\"cytarabine\"]], \"start\": [[122], [139]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[135]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"cytarabine\"], [\"methotrexate\"]], \"start\": [[139], [122]], \"entity_id\": [\"T13\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"Balint syndrome with irreversible posterior leukoencephalopathy on MRI\"]], \"start\": [[29]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19531695_12 | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[72]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"flecainide\"]], \"start\": [[44]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"flecainide\"], [\"flecainide\"], [\"paroxetine\"]], \"start\": [[44], [211], [226]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[191]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"flecainide\"], [\"paroxetine\"]], \"start\": [[211], [226]], \"entity_id\": [\"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"delirium\"]], \"start\": [[95]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[81]], \"entity_id\": [\"T13\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[63]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
8002140_2 | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[19]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Contact dermatitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"budesonide\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"budesonide\"]], \"start\": [[26]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8586895_3 | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[82]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a Japanese patient with vivax malaria\"]], \"start\": [[44]], \"entity_id\": [\"T3\"], \"Race\": {\"text\": [[\"Japanese\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"Prolongation of the QT interval\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"halofantrine\"]], \"start\": [[107]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"vivax malaria\"]], \"start\": [[68]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"halofantrine\"]], \"start\": [[107]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
7776854_3 | We report three cases of severe hepatotoxicity related to benzarone, a benzofuran derivative. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[47]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"three cases\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"three\"]], \"start\": [[10]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"severe hepatotoxicity\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"benzarone\"]], \"start\": [[58]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"benzarone\"]], \"start\": [[58]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8024670_1 | Four patients who manifested symptoms of the antiepileptic drug (AED) hypersensitivity syndrome during therapy with carbamazepine are reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"symptoms of\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"Four patients\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Population\": {\"text\": [[\"Four\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\"]], \"start\": [[70]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"antiepileptic drug (AED)\", \"during therapy with carbamazepine\"]], \"start\": [[45, 96]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"antiepileptic drug (AED)\"], [\"carbamazepine\"]], \"start\": [[45], [116]], \"entity_id\": [\"T8\", \"T9\"]}}}"
}
]
}
] |
11026106_1 | Minocycline as a cause of drug-induced autoimmune hepatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"autoimmune hepatitis\"]], \"start\": [[39]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Minocycline\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Minocycline\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
19434733_1 | Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Secondary acute myeloid leukemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"etoposide therapy\"]], \"start\": [[39]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"etoposide\"]], \"start\": [[39]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"haemophagocytic lymphohistiocytosis\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
16882109_1 | Allergic contact angioedema to benzoyl peroxide. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Allergic contact angioedema\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"benzoyl peroxide\"]], \"start\": [[31]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"benzoyl peroxide\"]], \"start\": [[31]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
1244265_1 | A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide (Neptazane) for an ophthalmologic problem. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[61]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A 60-year-old white man with chronic bronchitis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Age\": {\"text\": [[\"60-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T12\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[14]], \"entity_id\": [\"T13\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[20]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"chronic bronchitis\"]], \"start\": [[29]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"acute respiratory failure and metabolic acidosis\"]], \"start\": [[69]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"methazolamide (Neptazane)\"]], \"start\": [[151]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"methazolamide\"]], \"start\": [[151]], \"entity_id\": [\"T16\"]}, \"Disorder\": {\"text\": [[\"ophthalmologic problem\"]], \"start\": [[184]], \"entity_id\": [\"T17\"]}, \"Time_elapsed\": {\"text\": [[\"four days after\"]], \"start\": [[118]], \"entity_id\": [\"T18\"]}}}"
}
]
}
] |
14557583_2 | L-DOPA-induced excessive daytime sleepiness in PD: a placebo-controlled case with MSLT assessment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[7]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"L-DOPA\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"DOPA\"]], \"start\": [[2]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"daytime sleepiness\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
8384030_1 | CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"contributed\"]], \"start\": [[43]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"foscarnet\"]], \"start\": [[33]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"electrolyte disorders and symptomatology\"]], \"start\": [[62]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"this patient\"]], \"start\": [[106]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[19]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
17228132_1 | Acute drug induced hepatitis due to erlotinib. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[29]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute drug induced hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[36]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[36]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
9804082_2 | We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, voglibose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[103]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"3 diabetic patients\"]], \"start\": [[12]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[12]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"intolerable dizziness followed by nausea and vomiting\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"an initial administration of the alpha-glucosidase inhibitor, voglibose\"]], \"start\": [[109]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"diabetic\"]], \"start\": [[14]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"voglibose\"]], \"start\": [[171]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
9184269_1 | Although risk factors for MTX-induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"MTX\"]], \"start\": [[26]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[26]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"pulmonary toxicity\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA\"]], \"start\": [[80]], \"entity_id\": [\"T8\"], \"Population\": {\"text\": [[\"3 out of 5\"]], \"start\": [[96]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA\"]], \"start\": [[126]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
8936932_1 | Acute esmolol toxicity may be self-limiting because of its extremely short half-life. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"be\"]], \"start\": [[27]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"esmolol\"]], \"start\": [[6]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"esmolol\"]], \"start\": [[6]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"toxicity\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[23]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
7835785_2 | The association with prolonged unopposed estrogen-like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[16]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"development of ovarian endometrioid carcinoma\"]], \"start\": [[110]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"prolonged unopposed estrogen-like stimulation with tamoxifen\"]], \"start\": [[21]], \"entity_id\": [\"T5\"], \"Duration\": {\"text\": [[\"prolonged\"]], \"start\": [[21]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"tamoxifen\"]], \"start\": [[72]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"possible factor\"]], \"start\": [[87]], \"entity_id\": [\"T6\"], \"value\": true}}"
}
]
}
] |
7019786_2 | The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"acute tubular necrosis\"]], \"start\": [[55]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"The other woman had rheumatoid arthritis\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}, \"Treatment\": {\"text\": [[\"gentamicin and cefoxitin\"]], \"start\": [[99]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"rheumatoid arthritis\"]], \"start\": [[20]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"gentamicin\"], [\"cefoxitin\"]], \"start\": [[99], [114]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[110]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"gentamicin\"], [\"cefoxitin\"]], \"start\": [[99], [114]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
8053440_2 | One patient who received clindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"had\"]], \"start\": [[37]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"clindamycin\"]], \"start\": [[25]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"clindamycin\"]], \"start\": [[25]], \"entity_id\": [\"T17\"]}}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[0]], \"entity_id\": [\"T12\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"marked cholestasis, portal inflammation, bile duct injury and bile duct paucity (ductopenia)\"]], \"start\": [[66]], \"entity_id\": [\"T13\"]}, \"Severity\": {\"text\": [[\"marked\"]], \"start\": [[66]], \"entity_id\": [\"T16\"], \"value\": \"High\"}}"
}
]
}
] |
19531695_11 | A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[215]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"flecainide\"]], \"start\": [[204]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"flecainide\"]], \"start\": [[204]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"delirium\"]], \"start\": [[223]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"3 case reports\"]], \"start\": [[186]], \"entity_id\": [\"T10\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[186]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
11250985_1 | As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develops\"]], \"start\": [[184]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"spironolactone\"]], \"start\": [[89]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"spironolactone\"]], \"start\": [[89]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"diarrhoea\"]], \"start\": [[174]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[109]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
21045170_9 | When these cells are exposed to nicotinic acid, an exaggerated immune response is produced that may lead to pain, redness, and swelling at the injection site. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"produced\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"nicotinic acid\"]], \"start\": [[32]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"nicotinic acid\"]], \"start\": [[32]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"exaggerated immune response\"], [\"pain, redness, and swelling at the injection sit\"]], \"start\": [[51], [108]], \"entity_id\": [\"T8\", \"T10\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[96]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
15107195_1 | A case of heatstroke is reported in a 32-year-old man diagnosed with schizophrenia and on clozapine monotherapy. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"heatstroke\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"clozapine monotherapy\"]], \"start\": [[90]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[90]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"schizophrenia\"]], \"start\": [[69]], \"entity_id\": [\"T5\"]}}, \"Subject\": {\"text\": [[\"a 32-year-old man diagnosed with schizophrenia\"]], \"start\": [[36]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"32-year-old\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[50]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
282937_2 | Paraplegia following intrathecal cytosine arabinoside. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Paraplegia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"intrathecal cytosine arabinoside\"]], \"start\": [[21]], \"entity_id\": [\"T5\"], \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"cytosine arabinoside\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
6733633_1 | Cimetidine-induced fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Cimetidine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Cimetidine\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fever\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
3470173_5 | This case report illustrates the neurotoxicity unique to HDARAC. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[54]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"HDARAC\"]], \"start\": [[57]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"HDARAC\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"This case\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"neurotoxicity unique\"]], \"start\": [[33]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9433539_2 | Agranulocytosis associated with ticlopidine: a possible benefit with filgastim. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[16]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"ticlopidine\"]], \"start\": [[32]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[32]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Agranulocytosis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16005413_10 | Since SS is a clinical diagnosis, heightened clinician awareness of the possibility of SS among patients receiving SSRI or mirtazapine in combination with opioids may lead to earlier detection and avoidance of potentially lethal consequences. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"lead to\"]], \"start\": [[167]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"potentially lethal consequences\"]], \"start\": [[210]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"SSRI or mirtazapine in combination with opioids\"]], \"start\": [[115]], \"entity_id\": [\"T12\"], \"Drug\": {\"text\": [[\"SSRI\"], [\"mirtazapine\"], [\"opioids\"]], \"start\": [[115], [123], [155]], \"entity_id\": [\"T14\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[138]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"mirtazapine\"], [\"opioids\"], [\"SSRI\"]], \"start\": [[123], [155], [115]], \"entity_id\": [\"T15\", \"T16\", \"T14\"]}}]}}"
}
]
}
] |
19499966_4 | The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induces\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"sunitinib\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"gynaecomastia\"]], \"start\": [[41]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16463436_1 | Some patients develop hypersensitivity rash in response to HCQ. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"develop\"]], \"start\": [[14]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"Some patients\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"Some\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hypersensitivity rash\"]], \"start\": [[22]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"HCQ\"]], \"start\": [[59]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"HCQ\"]], \"start\": [[59]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
18676387_2 | To report a case of serotonin toxicity, presenting in the postoperative period, caused by an interaction between paroxetine (a selective serotonin reuptake inhibitor, SSRI) and fentanyl (a phenylpiperidine opioid). | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[80]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"serotonin toxicity\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"paroxetine\", \"fentanyl\"]], \"start\": [[113, 177]], \"entity_id\": [\"T11\"], \"Drug\": {\"text\": [[\"paroxetine\"], [\"fentanyl\"]], \"start\": [[113], [177]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[93]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"paroxetine\"], [\"fentanyl\"]], \"start\": [[113], [177]], \"entity_id\": [\"T12\", \"T13\"]}}]}}"
}
]
}
] |
20367573_1 | However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[99]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"newborns\"]], \"start\": [[30]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"newborns\"]], \"start\": [[30]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thrombocytosis\"]], \"start\": [[84]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"enoxaparin\"]], \"start\": [[110]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"enoxaparin\"]], \"start\": [[110]], \"entity_id\": [\"T8\"]}}, \"Negated\": {\"text\": [[\"no\"]], \"start\": [[55]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
9846036_7 | The case presented here documents adverse cardiac effects in a 28-year-old man who intentionally ingested 24 mg of risperidone--4 times the recommended dose. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"ingested\"]], \"start\": [[97]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"adverse cardiac effects\"]], \"start\": [[34]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"28-year-old man\"]], \"start\": [[63]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"28-year-old\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"24 mg of risperidone\"]], \"start\": [[106]], \"entity_id\": [\"T7\"], \"Dosage\": {\"text\": [[\"24 mg\"]], \"start\": [[106]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[115]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
12494253_2 | Anaphylaxis to cisplatin following nine previous uncomplicated cycles. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Anaphylaxis\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"cisplatin following nine previous uncomplicated cycles\"]], \"start\": [[15]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cisplatin\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Duration\": {\"text\": [[\"nine previous uncomplicated cycles\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
14746605_3 | To the best of the authors' knowledge, this is the first reported case of Propecia-associated cataract. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[83]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Propecia\"]], \"start\": [[74]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Propecia\"]], \"start\": [[74]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"cataract\"]], \"start\": [[94]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17381671_1 | Serotonin syndrome caused by interaction between citalopram and fentanyl. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[19]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"citalopram and fentanyl\"]], \"start\": [[49]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"citalopram\"], [\"fentanyl\"]], \"start\": [[49], [64]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"citalopram\"], [\"fentanyl\"]], \"start\": [[49], [64]], \"entity_id\": [\"T10\", \"T11\"]}}]}}"
}
]
}
] |
8149366_2 | We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[72]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"levo-dopa\"]], \"start\": [[62]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"levo-dopa\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"diphasic dyskinesias\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"parkinsonian patients\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"parkinsonian\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"reduce\"]], \"start\": [[143]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"parkinsonian patients\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"parkinsonian\"]], \"start\": [[35]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"subcutaneous apomorphine\"]], \"start\": [[115]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"abnormal movements\"]], \"start\": [[166]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"subcutaneous\"]], \"start\": [[115]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"apomorphine\"]], \"start\": [[128]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
11757641_3 | This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[73]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"acute lung injury\", \"persistent despite halofantrine therapy\"]], \"start\": [[31, 165]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"administration of mefloquine for a low-level Plasmodium falciparum malaria\", \"halofantrine therapy\"]], \"start\": [[79, 184]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"within hours\"]], \"start\": [[60]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"mefloquine\"], [\"halofantrine\"]], \"start\": [[97], [184]], \"entity_id\": [\"T7\", \"T9\"]}, \"Disorder\": {\"text\": [[\"low-level Plasmodium falciparum malaria\"]], \"start\": [[114]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
11837564_3 | Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"Warfarin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"bleeding\"]], \"start\": [[20]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"generally\"], [\"associated\"]], \"start\": [[29], [9]], \"entity_id\": [\"T7\", \"T8\"], \"value\": true}}"
}
]
}
] |
20076952_11 | The clinical use of itraconazole in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid-associated adverse effects. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"increase\"]], \"start\": [[103]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"itraconazole\", \"receiving multiple doses of oxycodone\"]], \"start\": [[20, 45]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"pain relief\"]], \"start\": [[87]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"oxycodone\"], [\"itraconazole\"]], \"start\": [[73], [20]], \"entity_id\": [\"T16\", \"T18\"]}, \"Dosage\": {\"text\": [[\"multiple doses\"]], \"start\": [[55]], \"entity_id\": [\"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[45]], \"entity_id\": [\"T19\"]}, \"Drug\": {\"text\": [[\"itraconazole\"], [\"oxycodone\"]], \"start\": [[20], [73]], \"entity_id\": [\"T18\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"opioid-associated adverse effects\"]], \"start\": [[124]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[36]], \"entity_id\": [\"T12\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[99]], \"entity_id\": [\"T15\"], \"value\": true}}"
}
]
}
] |
6251941_2 | Three cases of gold-related neuropathy are reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"gold\"]], \"start\": [[15]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"gold\"]], \"start\": [[15]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"neuropathy\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"Three cases\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"Three\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
17224428_2 | We report the case of a man, treated with mesalazine for Crohn's disease who developed drug-induced pericarditis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[77]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"drug-induced pericarditis\"]], \"start\": [[87]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a man\"]], \"start\": [[22]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"man\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"mesalazine\"]], \"start\": [[42]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[57]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"mesalazine\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
11483161_3 | We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurrence\"]], \"start\": [[14]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"spontaneous intracranial bleeding\"]], \"start\": [[28]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A\"]], \"start\": [[65]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"amprenavir (APV)\"]], \"start\": [[159]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"immunodeficiency virus (HIV)-infected adolescent with hemophilia A\"]], \"start\": [[74]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"amprenavir (APV)\"]], \"start\": [[159]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
17352036_3 | Under the suspicion of amiodarone-induced acute pancreatitis, amiodarone was substituted by propafenone. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"amiodarone\"]], \"start\": [[23]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"amiodarone\"]], \"start\": [[23]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
7661076_1 | Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"dangerous worsening of arrhythmia\"]], \"start\": [[68]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"patients with atrial flutter\"]], \"start\": [[105]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"adenosine\"]], \"start\": [[38]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"atrial flutter.\"]], \"start\": [[119]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"adenosine\"]], \"start\": [[38]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
6197014_1 | Salicylate hepato toxicity in rheumatic fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"toxicity\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Salicylate\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"rheumatic fever\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"Salicylate\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"hepato toxicity\"]], \"start\": [[11]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
17189581_2 | A case of serotonin syndrome that developed during concurrent linezolid and fluoxetine is presented. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"concurrent linezolid and fluoxetine\"]], \"start\": [[51]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"linezolid\"], [\"fluoxetine\"]], \"start\": [[62], [76]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"concurrent\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"fluoxetine\"]], \"start\": [[62], [76]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
15866658_1 | Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[71]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"MMF\"]], \"start\": [[109]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"MMF\"]], \"start\": [[109]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"neutropenia\"]], \"start\": [[81]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"four patients who underwent liver transplantation\"]], \"start\": [[17]], \"entity_id\": [\"T6\"], \"Population\": {\"text\": [[\"four\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"liver transplantation\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
2931445_2 | A study of in vitro reactivity to L-T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed leukopenia during treatment with L-T4. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[157]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"leukopenia\"]], \"start\": [[167]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"a patient with Hashimoto's disease\"]], \"start\": [[118]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"L-T4\"]], \"start\": [[200]], \"entity_id\": [\"T11\"], \"Disorder\": {\"text\": [[\"Hashimoto's disease\"]], \"start\": [[133]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"L-T4\"]], \"start\": [[200]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
8792511_2 | Methemoglobinemia is another common finding among patients receiving dapsone therapy, but rarely does it result in prominent symptoms other than transient pallor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"receiving\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"dapsone therapy\"]], \"start\": [[69]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"dapsone\"]], \"start\": [[69]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[50]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Methemoglobinemia\", \"transient pallor\"]], \"start\": [[0, 145]], \"entity_id\": [\"T3\"]}}"
}
]
}
] |
3470173_3 | During the first treatment, dysarthria and ataxia were seen after completion of the patient's eighth and final dose of HDARAC. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"seen\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"dysarthria and ataxia\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"HDARAC\"]], \"start\": [[119]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"HDARAC\"]], \"start\": [[119]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"the patient's\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
3143551_4 | Four weeks earlier she had developed hepatopathy during a regimen of carbamazepine, lynestrenol and sodium valproate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[19]], \"entity_id\": [\"T5\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[19]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hepatopathy\"]], \"start\": [[37]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"carbamazepine, lynestrenol and sodium valproate\"]], \"start\": [[69]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"carbamazepine\"], [\"lynestrenol\"], [\"sodium valproate\"]], \"start\": [[69], [84], [100]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}}}"
}
]
}
] |
1420650_3 | We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occur\"]], \"start\": [[82]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"even at low or moderate dosage levels\", \"certain drugs as lithium or clozapine are used in combination with CBZ\"]], \"start\": [[88, 130]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"CBZ\"], [\"lithium\"], [\"clozapine\"]], \"start\": [[197], [147], [158]], \"entity_id\": [\"T15\", \"T16\", \"T17\"]}, \"Dosage\": {\"text\": [[\"low or moderate dosage\"]], \"start\": [[96]], \"entity_id\": [\"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[180]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"CBZ\"], [\"lithium\"]], \"start\": [[197], [147]], \"entity_id\": [\"T15\", \"T16\"]}}, {\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[180]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"CBZ\"], [\"clozapine\"]], \"start\": [[197], [158]], \"entity_id\": [\"T15\", \"T17\"]}}]}, \"Effect\": {\"text\": [[\"asterixis\"]], \"start\": [[12]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[78]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
20178709_3 | We report here a rare case of pleuropericarditis due to methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[49]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"pleuropericarditis\"]], \"start\": [[30]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"methotrexate\"]], \"start\": [[56]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[56]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a rare case\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
3677571_2 | A case of phenytoin-induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"phenytoin\"]], \"start\": [[10]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[10]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"hepatitis with mononucleosis\"]], \"start\": [[28]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
10099659_14 | We also discuss whether screening for DPD deficiency is warranted to identify patients at risk for severe toxicities from 5-FU treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[90]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"5-FU treatment\"]], \"start\": [[122]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"5-FU\"]], \"start\": [[122]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"severe toxicities\"]], \"start\": [[99]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[78]], \"entity_id\": [\"T11\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[99]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
10102531_2 | We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"undergoing\"]], \"start\": [[123]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"reversible encephalopathy syndrome\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a 16-year-old girl with acute myelogenous leukemia (AML)\"]], \"start\": [[58]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"16-year-old\"]], \"start\": [[60]], \"entity_id\": [\"T9\"]}, \"Gender\": {\"text\": [[\"girl\"]], \"start\": [[72]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin\"]], \"start\": [[141]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"acute myelogenous leukemia\"]], \"start\": [[82]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"idarubicin\"], [\"BH-AC\"]], \"start\": [[239], [180]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[235]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"idarubicin\"], [\"BH-AC\"]], \"start\": [[239], [180]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
24429012_10 | Concurrent use of vismodegib and warfarin was deemed the probable cause of acute INR elevation in this case, suggesting the need for close monitoring of INR values in patients receiving this combination of drugs. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[66]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"vismodegib and warfarin\"]], \"start\": [[18]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"vismodegib\"], [\"warfarin\"]], \"start\": [[18], [33]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[29]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"vismodegib\"], [\"warfarin\"]], \"start\": [[18], [33]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"acute INR elevation\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[57]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
11834188_2 | Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"documented\"]], \"start\": [[99]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"cutaneous side-effects\"]], \"start\": [[72]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Captopril\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Captopril\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
18784429_3 | High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[94]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a pregnant woman with Crohn's disease\"]], \"start\": [[32]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"pregnant\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[43]], \"entity_id\": [\"T8\"]}}, \"Treatment\": {\"text\": [[\"High-dose methylprednisolone\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"Crohn's disease\"]], \"start\": [[54]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"High-dose\"], [\"methylprednisolone\"]], \"start\": [[0], [10]], \"entity_id\": [\"T11\", \"T12\"]}}, \"Effect\": {\"text\": [[\"adrenal suppression in her newborn\"]], \"start\": [[74]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
17224428_1 | Cardiac hypersensitivity and myopericarditis have been reported during long-term treatment with mesalazine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[55]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Cardiac hypersensitivity and myopericarditis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"long-term treatment with mesalazine\"]], \"start\": [[71]], \"entity_id\": [\"T7\"], \"Duration\": {\"text\": [[\"long-term\"]], \"start\": [[71]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"mesalazine\"]], \"start\": [[96]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
6311654_6 | It is concluded that 'cerebral atrophy' on CT scans may represent an accumulative effect of ACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"represent\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"cerebral atrophy\"]], \"start\": [[22]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"ACTH\"]], \"start\": [[92]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"ACTH\"], [\"ACTH\"]], \"start\": [[92], [106]], \"entity_id\": [\"T10\", \"T11\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[52]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
12135176_1 | Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[49]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"polymorphic ventricular tachycardia\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"verapamil\"]], \"start\": [[82]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"paroxysmal supraventricular tachycardia\"]], \"start\": [[100]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[82]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
15162903_3 | Fatal acute encephalomyelitis after a single dose of intrathecal methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Fatal acute encephalomyelitis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"single dose of intrathecal methotrexate\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Dosage\": {\"text\": [[\"single dose\"]], \"start\": [[38]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"intrathecal\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[65]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"Fatal\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"value\": \"High\"}}"
}
]
}
] |
18465737_2 | The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[77]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"incomplete posterior hyaloid detachment (PHD)\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"intravitreal pegaptanib\"]], \"start\": [[87]], \"entity_id\": [\"T6\"], \"Route\": {\"text\": [[\"intravitreal\"]], \"start\": [[87]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"pegaptanib\"]], \"start\": [[100]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"DME\"]], \"start\": [[120]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"one case\"]], \"start\": [[19]], \"entity_id\": [\"T10\"]}}"
}
]
}
] |
3612639_1 | Pulmonary edema as a delayed complication of ritodrine therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[29]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Pulmonary edema\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"ritodrine\"]], \"start\": [[45]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"ritodrine\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
15685264_1 | Carbamazepine toxicity following Oxybutynin and Dantrolene administration: a case report. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[23]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Oxybutynin and Dantrolene\"]], \"start\": [[33]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"Oxybutynin\"], [\"Dantrolene\"]], \"start\": [[33], [48]], \"entity_id\": [\"T10\", \"T11\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[44]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"Dantrolene\"], [\"Oxybutynin\"]], \"start\": [[48], [33]], \"entity_id\": [\"T11\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"Carbamazepine toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
18633310_1 | Multiple seizures after bupropion overdose in a small child. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Multiple seizures\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"bupropion overdose\"]], \"start\": [[24]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"bupropion\"]], \"start\": [[24]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"overdose\"]], \"start\": [[34]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"a small child\"]], \"start\": [[46]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"small child\"]], \"start\": [[48]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
19537383_2 | Sorafenib, a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas, received FDA approval in 2005. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[57]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"Sorafenib\", \"a multitargeted kinase inhibitor\"]], \"start\": [[0, 11]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Sorafenib\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"unresectable hepatocellular carcinoma\"], [\"advanced renal cell carcinomas\"]], \"start\": [[70], [112]], \"entity_id\": [\"T10\", \"T11\"]}}}"
}
]
}
] |
1174301_2 | Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[17]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Triiodothyronine\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Disorder\": {\"text\": [[\"ophthalmic Graves\"]], \"start\": [[43]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"Triiodothyronine\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"thyrotoxicosis\"]], \"start\": [[25]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
17526968_1 | Bleomycin induced hyperpigmentation with yolk sac tumor. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"Bleomycin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Bleomycin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"hyperpigmentation with yolk sac tumor\"]], \"start\": [[18]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
19034138_5 | PURPOSE: To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long-term amantadine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[63]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"bilateral corneal endothelial dysfunction\"]], \"start\": [[21]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a patient with Parkinson disease\"]], \"start\": [[66]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"long-term amantadine\"]], \"start\": [[120]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"Parkinson disease\"]], \"start\": [[81]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[130]], \"entity_id\": [\"T9\"]}, \"Duration\": {\"text\": [[\"ong-term\"]], \"start\": [[121]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
2140997_1 | A case of severe acute hepatitis caused by cyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[33]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"acute hepatitis\"]], \"start\": [[17]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[43]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyproterone acetate\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"prostatic carcinoma\"]], \"start\": [[89]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"a 71 year old man with prostatic carcinoma\"]], \"start\": [[66]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"71 year old\"]], \"start\": [[68]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[80]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[10]], \"entity_id\": [\"T12\"], \"value\": \"High\"}}"
}
]
}
] |
2309833_2 | Insulin-dependent diabetes mellitus associated with danazol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[36]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"danazol\"]], \"start\": [[52]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"danazol\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Insulin-dependent diabetes mellitus\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
10458196_4 | CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[40]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Topical brimonidine\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"brimonidine\"]], \"start\": [[21]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"Topical\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"central nervous system depression\"]], \"start\": [[56]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"infants\"]], \"start\": [[93]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"infants\"]], \"start\": [[93]], \"entity_id\": [\"T7\"]}}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[33]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
10707759_1 | Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[11]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"a patient with the LEOPARD syndrome\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"Flecainide\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"LEOPARD syndrome.\"]], \"start\": [[87]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"pneumonitis with acute respiratory failure\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
1433432_1 | Seizure with hyponatremia in a child prescribed desmopressin for nocturnal enuresis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[26]], \"entity_id\": [\"T2\"]}, \"Treatment\": {\"text\": [[\"desmopressin\"]], \"start\": [[48]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"desmopressin\"]], \"start\": [[48]], \"entity_id\": [\"T14\"]}, \"Disorder\": {\"text\": [[\"nocturnal enuresis\"]], \"start\": [[65]], \"entity_id\": [\"T15\"]}}, \"Effect\": {\"text\": [[\"Seizure with hyponatremia\"]], \"start\": [[0]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"a child\"]], \"start\": [[29]], \"entity_id\": [\"T1\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[31]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
23624139_10 | Risks and benefits of co-treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"recommended\"]], \"start\": [[115]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"therapeutic alternatives to NSAIDs\"]], \"start\": [[70]], \"entity_id\": [\"T9\"], \"Disorder\": {\"text\": [[\"central DI\"]], \"start\": [[144]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"NSAIDs\"]], \"start\": [[98]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"patients with central DI\"]], \"start\": [[130]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"in order to improve DDAVP safety\"]], \"start\": [[155]], \"entity_id\": [\"T1\"]}}"
}
]
}
] |
15685264_6 | She had been treated by Carbamazepine 1000 mg/day for neuropathic pain for 2 years without clinical or laboratory signs of toxicity. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[13]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Carbamazepine 1000 mg/day\"]], \"start\": [[24]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"neuropathic pain\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"Carbamazepine\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"1000 mg/day\"]], \"start\": [[38]], \"entity_id\": [\"T11\"]}, \"Time_elapsed\": {\"text\": [[\"2 years\"]], \"start\": [[75]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
9509511_1 | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the hepatotoxicity developed. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"given\"]], \"start\": [[136]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"vincristine and actinomycin D\"]], \"start\": [[90]], \"entity_id\": [\"T18\"], \"Drug\": {\"text\": [[\"vincristine\"], [\"actinomycin D\"]], \"start\": [[90], [106]], \"entity_id\": [\"T14\", \"T15\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[102]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"vincristine\"], [\"actinomycin D\"]], \"start\": [[90], [106]], \"entity_id\": [\"T14\", \"T15\"]}}]}, \"Effect\": {\"text\": [[\"hepatotoxicity developed\"]], \"start\": [[153]], \"entity_id\": [\"T8\"]}}"
},
{
"event_id": "E4",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E4\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"given\"]], \"start\": [[136]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"hepatotoxicity developed\"]], \"start\": [[153]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"chemotherapeutics, including vincristine, actinomycin D, and epirubicin\"]], \"start\": [[4]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"vincristine\"], [\"actinomycin D\"], [\"epirubicin\"]], \"start\": [[33], [46], [65]], \"entity_id\": [\"T10\", \"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E3\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[61]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"epirubicin\"], [\"actinomycin D\"], [\"vincristine\"]], \"start\": [[65], [46], [33]], \"entity_id\": [\"T12\", \"T11\", \"T10\"]}}]}}"
}
]
}
] |
11816261_1 | After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[72]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"second dose of metoclopramide\"]], \"start\": [[8]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"metoclopramide\"]], \"start\": [[23]], \"entity_id\": [\"T19\"]}}, \"Effect\": {\"text\": [[\"confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension\"]], \"start\": [[88]], \"entity_id\": [\"T17\"]}}"
}
]
}
] |
17364199_4 | We report the first case of tuberculous uveitis due to etanercept. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"tuberculous uveitis\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"etanercept\"]], \"start\": [[55]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"etanercept\"]], \"start\": [[55]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
10516999_1 | Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[24]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Acute hyperphosphatemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"sodium phosphate enema\"]], \"start\": [[34]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"sodium phosphate\"]], \"start\": [[34]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"enema\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a patient with liver dysfunction and chronic renal failure\"]], \"start\": [[60]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"liver dysfunction and chronic renal failure\"]], \"start\": [[75]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
12757344_2 | We discuss the association between carbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[15]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"carbamazepine\"]], \"start\": [[35]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"carbamazepine\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[53]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
16882112_7 | Use of the Naranjo adverse drug reaction probability algorithm indicated a probable relationship between serotonin syndrome and treatment with lithium and venlafaxine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"a probable relationship between\"]], \"start\": [[73]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[105]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"treatment with lithium and venlafaxine\"]], \"start\": [[128]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"lithium\"], [\"venlafaxine\"]], \"start\": [[143], [155]], \"entity_id\": [\"T11\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[151]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"venlafaxine\"]], \"start\": [[143], [155]], \"entity_id\": [\"T11\", \"T13\"]}}]}, \"Speculated\": {\"text\": [[\"probable\"]], \"start\": [[75]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
19203515_3 | The exact mechanism of IVIG-associated acute renal failure remains unclear. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"IVIG\"]], \"start\": [[23]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"IVIG\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"acute renal failure\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Speculated\": {\"text\": [[\"unclear\"]], \"start\": [[67]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
1849334_2 | We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[73]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"a high dosage of the new diuretic muzolimine (range 240 to 1440 mg per day)\"]], \"start\": [[89]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"diuretic muzolimine\"]], \"start\": [[114]], \"entity_id\": [\"T12\"]}, \"Freq\": {\"text\": [[\"per day\"]], \"start\": [[156]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"range 240 to 1440 mg\"]], \"start\": [[135]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"fatal neuromyeloencephalopathy\"]], \"start\": [[165]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"7 patients (2 women, 5 men) with chronic renal failure\"]], \"start\": [[13]], \"entity_id\": [\"T16\"], \"Disorder\": {\"text\": [[\"chronic renal failure\"]], \"start\": [[46]], \"entity_id\": [\"T7\"]}, \"Population\": {\"text\": [[\"7\"]], \"start\": [[13]], \"entity_id\": [\"T11\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[165]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
1580986_2 | Two renal transplant patients developed anemia during treatment of hypertension with enalapril medication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[30]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"Two renal transplant patients\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"renal transplant\"]], \"start\": [[4]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"anemia\"]], \"start\": [[40]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"enalapril medication\"]], \"start\": [[85]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"hypertension\"]], \"start\": [[67]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"enalapril\"]], \"start\": [[85]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
7787496_1 | Sotalol-induced bradycardia reversed by glucagon. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"reversed\"]], \"start\": [[28]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"glucagon\"]], \"start\": [[40]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Sotalol-induced bradycardia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"glucagon\"]], \"start\": [[40]], \"entity_id\": [\"T8\"]}}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[8]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Sotalol\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"Sotalol\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}, \"Effect\": {\"text\": [[\"bradycardia\"]], \"start\": [[16]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
9892272_4 | The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of alteplase should strongly suggest the possibility of diffuse subfascial hematoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[4]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"cutaneous ecchymosis\", \"a sudden fall in hemoglobin\", \"diffuse subfascial hematoma\"]], \"start\": [[19, 56, 165]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"alteplase\"]], \"start\": [[112]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"alteplase\"]], \"start\": [[112]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"strongly sugges\"]], \"start\": [[129]], \"entity_id\": [\"T11\"], \"value\": true}}"
}
]
}
] |
11545487_7 | We report a case of papillary necrosis in a patient treated with indinavir. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"papillary necrosis\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"indinavir\"]], \"start\": [[65]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"indinavir\"]], \"start\": [[65]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
9247841_3 | Generalized maculopapular and papular purpuric eruptions are perhaps the most common thionamide-induced reactions. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[96]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Generalized maculopapular and papular purpuric eruptions\", \"reactions\"]], \"start\": [[0, 104]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"thionamide\"]], \"start\": [[85]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"thionamide\"]], \"start\": [[85]], \"entity_id\": [\"T11\"]}}, \"Speculated\": {\"text\": [[\"perhaps\"]], \"start\": [[61]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
8276031_6 | Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[25]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"children\"]], \"start\": [[120]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"children\"]], \"start\": [[120]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"Imidazoline\", \"overdose or accidental ingestion but also after normal therapeutic usage\"]], \"start\": [[0, 32]], \"entity_id\": [\"T7\"], \"Route\": {\"text\": [[\"ingestion\"]], \"start\": [[55]], \"entity_id\": [\"T12\"]}, \"Dosage\": {\"text\": [[\"overdose or accidental\", \"but also after normal therapeutic usage\"]], \"start\": [[32, 65]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"intoxication\"]], \"start\": [[12]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
12121061_2 | A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[85]], \"entity_id\": [\"T18\"]}, \"Treatment\": {\"text\": [[\"ticlopidine\"]], \"start\": [[73]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[73]], \"entity_id\": [\"T22\"]}}, \"Subject\": {\"text\": [[\"50-year-old diabetic and hypertensive male patient\"]], \"start\": [[2]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"diabetic and hypertensive\"]], \"start\": [[14]], \"entity_id\": [\"T16\"]}, \"Age\": {\"text\": [[\"50-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T20\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[40]], \"entity_id\": [\"T21\"]}}, \"Effect\": {\"text\": [[\"marrow aplasia\"]], \"start\": [[93]], \"entity_id\": [\"T19\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[214]], \"entity_id\": [\"T27\"]}, \"Subject\": {\"text\": [[\"50-year-old diabetic and hypertensive male patient\"]], \"start\": [[2]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"diabetic and hypertensive\"]], \"start\": [[14]], \"entity_id\": [\"T16\"]}, \"Age\": {\"text\": [[\"50-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T20\"]}, \"Gender\": {\"text\": [[\"male\"]], \"start\": [[40]], \"entity_id\": [\"T21\"]}}, \"Effect\": {\"text\": [[\"experienced complete recovery\"]], \"start\": [[184]], \"entity_id\": [\"T25\"]}, \"Treatment\": {\"text\": [[\"cyclosporine\"]], \"start\": [[219]], \"entity_id\": [\"T24\"], \"Disorder\": {\"text\": [[\"ticlopidine-induced marrow aplasia\"]], \"start\": [[73]], \"entity_id\": [\"T28\"]}, \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[219]], \"entity_id\": [\"T26\"]}}}"
}
]
}
] |
2378415_2 | A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[115]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"a single dose of intravenous methotrexate\"]], \"start\": [[190]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"intracranial osteosarcoma\"]], \"start\": [[15]], \"entity_id\": [\"T9\"]}, \"Freq\": {\"text\": [[\"a single dose\"]], \"start\": [[190]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"intravenous\"]], \"start\": [[207]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"methotrexate\"]], \"start\": [[219]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"cerebral edema and brainstem herniation\"]], \"start\": [[131]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"hereditary retinoblastoma\"]], \"start\": [[89]], \"entity_id\": [\"T1\"]}}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[125]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
8255797_2 | Neutropenia is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, captopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[42]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Neutropenia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the angiotensin-converting enzyme (ACE) inhibitor, captopril\"]], \"start\": [[70]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"captopril\"]], \"start\": [[121]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
17522786_1 | INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and raised intracranial pressure (ICP) after severe sodium valproic acid (VPA) intoxication. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[149]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"patient\"]], \"start\": [[72]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"severe cerebral swelling and raised intracranial pressure (ICP)\", \"intoxication\"]], \"start\": [[85, 189]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"sodium valproic acid (VPA)\"]], \"start\": [[162]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"sodium valproic acid\"]], \"start\": [[162]], \"entity_id\": [\"T12\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[155]], \"entity_id\": [\"T11\"], \"value\": \"High\"}}"
}
]
}
] |